The FDA has cleared Box DICOM Viewer, part of the Box for Healthcare solution.
Box has received FDA clearance for its DICOM Viewer, the company announced at HIMSS 2016.
Box, an enterprise content management platform, developed a solution tailored for hospitals that streamlines referral management, enables medical professionals to share and view DICOM files, and provides access to critical data that is often “trapped in proprietary hospital-based enterprise systems,” a release said.
The Box DICOM viewer is part of the Box for Healthcare solution, which includes a content management platform that allows hospitals to securely share and manage content in the cloud from any device in real time; Box Governance, which enables customers to comply with regulatory policies, satisfy e-discovery requests, and manage sensitive information; Box Consulting Services, which provides expertise to help customers transform their clinical workflows with custom integration; and Partner Integration Capabilities, which supports HIPAA-compliant faxing services and communication with hospital based record systems, the company said.
The Box DICOM Viewer is now generally available and has been FDA cleared as a Class II Medical Device, and can therefore be used for diagnostic purposes.[[{"type":"media","view_mode":"media_crop","fid":"46782","attributes":{"alt":"Box DICOM Viewer","class":"media-image","id":"media_crop_3507474655434","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"5454","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":"Image courtesy of Box.","typeof":"foaf:Image"}}]]
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.